Some restrictions apply to the distribution and use of deletion lines from Exelixis. Commercial researchers must obtain a use license from Exelixis Inc. to work with these stocks.
The entry in the Basis column below indicates how the stock center updated breakpoint sequence coordinates: R5 flank = insertion flanking sequence aligned to release 5 genome assembly (per FlyBase or R. Hoskins, personal communication) R3 author statement->R5 = Parks et al. release 3 sequence coordinate mapped forward to release 5
A single entry in Basis applies to both endpoints; two values indicate the basis of left and right endpoints, respectively. Values based on R3 author statements should be treated as approximations.
Our complementation tests have shown that 10% of the stocks in the original Exelixis deletion collection did not carry the described deletion and that 77% of the stocks are deficient. The remaining 13% are unconfirmed.